PubRank

D T Dexter

Author PubWeight™ 24.20‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994 2.65
2 Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease. Neurogenetics 2006 1.79
3 Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 1992 1.45
4 Increased nigral iron content in postmortem parkinsonian brain. Lancet 1987 1.39
5 Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol 1994 1.29
6 Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease. FEBS Lett 1994 1.23
7 Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. J Neurol Sci 1998 1.18
8 Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease. Neurogenetics 2006 1.16
9 Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease. Free Radic Res 1996 1.01
10 Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females. Neuroscience 2003 0.97
11 Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease. Neuroreport 2001 0.95
12 Analysis of alpha-synuclein, dopamine and parkin pathways in neuropathologically confirmed parkinsonian nigra. Acta Neuropathol 2007 0.94
13 Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov Disord 2001 0.92
14 Evaluation of the effects of swainsonine, captopril, tangeretin and nobiletin on the biological behaviour of brain tumour cells in vitro. Neuropathol Appl Neurobiol 2001 0.92
15 Nicotinamide N-methyltransferase expression in SH-SY5Y neuroblastoma and N27 mesencephalic neurones induces changes in cell morphology via ephrin-B2 and Akt signalling. Cell Death Dis 2013 0.91
16 Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease. Eur J Neurosci 2005 0.90
17 Full and partial peroxisome proliferation-activated receptor-γ agonists, but not δ agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression. J Neuroimmunol 2012 0.90
18 Comparative study of commercially available anti-alpha-synuclein antibodies. Neuropathol Appl Neurobiol 2006 0.87
19 Chelating agents for neurodegenerative diseases. Curr Med Chem 2012 0.84
20 Effects of anaesthetics on the loss of nigrostriatal dopaminergic neurons by 6-hydroxydopamine in rats. J Neural Transm (Vienna) 2005 0.78
21 The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease. J Pharm Pharmacol 2004 0.76
22 Comparison of HPLC and enzymatic recycling assays for the measurement of oxidized glutathione in rat brain. J Pharm Pharmacol 1997 0.76
23 Chronic trifluoperazine treatment does not induce lipid peroxidation in the rat cortex. Neurosci Lett 1987 0.75
24 (-)-Deprenyl can induce soluble superoxide dismutase in rat striata. J Neural Transm Gen Sect 1991 0.75